PHKA2-AS1

Across TCGA pan-cancer cohorts, PHKA2-AS1 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated PHKA2-AS1 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PHKA2-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PHKA2-AS1 expression acts as an unfavorable survival marker, although some lineages such as KIRC and PAAD show a favorable association.

STAD, ACC, and LGG are the cancer types where PHKA2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	IV	0.254	0.642	<.001	81	view →
ACC	OS	Median	All	0.416	0.820	<.001	75	view →
LGG	DFS	Median	All	0.645	0.824	<.001	52	view →
COAD	OS	Median	IV	0.482	0.794	.003	38	view →
LAML	DFS	Quartile	All	0.301	0.714	.004	36	view →
BLCA	OS	Median	III,IV	0.154	0.443	.003	21	view →
KIRC	DFS	Median	IV	0.624	0.370	<.001	20	view →
PAAD	DFS	Median	All	0.358	0.191	.003	19	view →
DLBC	OS	Median	All	0.739	1.000	.004	16	view →
HNSC	DFS	Median	III,IV	0.738	0.623	.024	16	view →
LIHC	OS	Tertile	All	0.569	0.800	.009	15	view →
CHOL	DFS	Quartile	All	0.116	1.000	.019	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

PHKA2-AS1–STAD (DFS)

Open the STAD breakdown →